CMPX

Compass Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · compasstherapeutics.com

$1.94

Mkt Cap $268.3M

52w Low $1.61 6.3% of range 52w High $6.88

50d MA $5.12 200d MA $4.61

P/E (TTM) -4.7x

EV/EBITDA -11.3x

P/B 1.6x

Debt/Equity 0.1x

ROE -33.8%

P/FCF -17.2x

RSI (14) —

ATR (14) —

Beta 1.30

50d MA $5.12

200d MA $4.61

Avg Volume 6.0M

About

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, whi…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 5, 2026	AMC	-0.10	-0.09	+10.0%	5.53	-2.2%	-0.4%	-2.0%	+0.7%	+1.1%	-6.1%	-0.7%	—
Nov 5, 2025	AMC	-0.14	-0.08	+42.9%	3.82	+0.0%	+4.7%	+10.7%	+12.0%	+21.2%	+28.3%	+44.8%	—
Aug 11, 2025	AMC	-0.13	-0.14	-7.7%	3.34	+3.6%	-5.1%	-7.2%	-11.7%	-11.1%	-14.1%	+5.4%	—
May 8, 2025	AMC	-0.12	-0.12	+0.0%	1.78	+1.7%	+2.2%	+12.9%	+12.4%	+12.4%	+13.5%	+44.4%	—
Feb 27, 2025	AMC	-0.10	-0.11	-10.0%	2.92	+2.4%	-0.7%	-6.5%	-4.8%	-5.1%	-10.3%	-34.9%	—
Nov 12, 2024	AMC	-0.11	-0.08	+27.3%	1.79	+2.2%	-5.6%	-11.2%	-22.9%	-24.6%	-20.7%	-15.6%	—
Aug 12, 2024	AMC	-0.10	-0.10	+0.0%	1.13	+3.5%	+6.2%	+0.9%	+2.7%	+2.7%	+5.3%	+32.7%	—
May 13, 2024	AMC	-0.11	-0.08	+27.3%	1.56	-2.6%	+3.8%	-1.3%	+2.6%	+2.6%	+2.6%	-23.1%	—
Mar 21, 2024	AMC	-0.09	-0.11	-22.2%	2.24	+1.8%	-4.9%	-8.5%	-11.6%	-8.5%	-11.6%	-33.5%	—
Nov 9, 2023	AMC	-0.11	-0.08	+27.3%	1.61	+3.1%	-3.7%	-13.0%	-5.0%	-8.1%	-6.8%	-1.2%	—
Aug 3, 2023	AMC	-0.08	-0.09	-12.5%	2.66	+0.8%	-5.3%	-8.6%	-6.8%	-1.1%	-3.4%	-12.4%	—
May 4, 2023	AMC	-0.11	-0.06	+45.5%	2.96	+1.7%	+11.8%	+17.6%	+14.9%	+13.9%	+11.5%	+2.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Canaccord Genuity	Maintains	Buy → Buy	—	$1.79	$1.91	+6.7%	+2.8%	-6.7%	-1.1%	+9.5%	—
Apr 28	Citizens	Maintains	Market Outperform → Market Outperform	—	$1.79	$1.91	+6.7%	+2.8%	-6.7%	-1.1%	+9.5%	—
Apr 28	Raymond James	Downgrade	Outperform → Mkt Perform	—	$1.79	$1.91	+6.7%	+2.8%	-6.7%	-1.1%	+9.5%	—
Apr 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.03	$1.77	-64.8%	-64.4%	-63.4%	-66.8%	-64.8%	-61.0%
Apr 27	D. Boral Capital	Maintains	Buy → Buy	—	$5.03	$1.77	-64.8%	-64.4%	-63.4%	-66.8%	-64.8%	-61.0%
Mar 24	Guggenheim	Maintains	Buy → Buy	—	$5.04	$4.96	-1.6%	+5.8%	+8.9%	+5.8%	+3.4%	+1.2%
Jan 6	D. Boral Capital	Maintains	Buy → Buy	—	$4.99	$4.91	-1.6%	-1.6%	+9.2%	+3.6%	+7.2%	+4.4%
Nov 5	D. Boral Capital	Maintains	Buy → Buy	—	$3.79	$3.82	+0.8%	+0.8%	+5.5%	+11.6%	+12.9%	+22.2%
Aug 12	Guggenheim	Maintains	Buy → Buy	—	$3.34	$3.46	+3.6%	-5.1%	-7.2%	-11.7%	-11.1%	-14.1%
Aug 12	D. Boral Capital	Maintains	Buy → Buy	—	$3.34	$3.46	+3.6%	-5.1%	-7.2%	-11.7%	-11.1%	-14.1%
May 9	Guggenheim	Maintains	Buy → Buy	—	$1.78	$1.81	+1.7%	+2.2%	+12.9%	+12.4%	+12.4%	+13.5%
Apr 28	D. Boral Capital	Maintains	Buy → Buy	—	$1.94	$1.94	+0.0%	-2.1%	-5.2%	-4.1%	-6.2%	-2.6%
Apr 22	Guggenheim	Maintains	Buy → Buy	—	$1.78	$1.80	+1.1%	+11.2%	+16.3%	+19.1%	+9.0%	+6.7%
Apr 21	D. Boral Capital	Maintains	Buy → Buy	—	$1.75	$1.72	-1.7%	+1.7%	+13.1%	+18.3%	+21.1%	+10.9%
Apr 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.75	$1.72	-1.7%	+1.7%	+13.1%	+18.3%	+21.1%	+10.9%
Apr 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.61	$1.62	+0.6%	-9.3%	-2.5%	-1.2%	+8.7%	+2.5%
Apr 2	Guggenheim	Maintains	Buy → Buy	—	$2.24	$2.35	+4.9%	-24.6%	-28.1%	-34.8%	-29.9%	-29.0%
Apr 2	Leerink Partners	Upgrade	Market Perform → Outperform	—	$2.24	$2.35	+4.9%	-24.6%	-28.1%	-34.8%	-29.9%	-29.0%
Apr 1	D. Boral Capital	Maintains	Buy → Buy	—	$1.90	$1.87	-1.6%	+17.9%	-11.1%	-15.3%	-23.2%	-17.4%
Feb 27	D. Boral Capital	Maintains	Buy → Buy	—	$2.97	$3.00	+1.0%	-1.7%	-2.4%	-8.1%	-6.4%	-6.7%
Feb 25	D. Boral Capital	Maintains	Buy → Buy	—	$3.11	$3.10	-0.3%	-4.5%	-4.5%	-6.1%	-6.8%	-12.2%
Feb 10	Jefferies	Maintains	Buy → Buy	—	$3.50	$3.59	+2.6%	+11.4%	+4.3%	+7.1%	-1.4%	-3.4%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.86	$1.91	+2.7%	-4.8%	+4.8%	+7.5%	+32.8%	+34.4%
Jan 8	D. Boral Capital	Maintains	Buy → Buy	—	$1.43	$1.60	+11.9%	+30.1%	+23.8%	+36.4%	+39.9%	+72.7%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.43	$1.60	+11.9%	+30.1%	+23.8%	+36.4%	+39.9%	+72.7%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.59	$1.62	+1.9%	-13.2%	-15.1%	-10.7%	-13.8%	-13.2%
Nov 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.90	$1.90	+0.0%	-5.8%	-11.1%	-16.3%	-27.4%	-28.9%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.80	$1.87	+3.9%	+5.6%	-0.6%	-6.1%	-11.7%	-23.3%
Sep 16	Ladenburg Thalmann	Upgrade	Neutral → Buy	—	$1.65	$1.75	+6.1%	+3.6%	+0.6%	-1.2%	+4.8%	+0.6%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.09	$1.12	+2.8%	+3.7%	+10.1%	+4.6%	+6.4%	+6.4%
Aug 7	Wedbush	Maintains	Outperform → Outperform	—	$0.96	$1.06	+10.1%	-6.5%	+4.9%	+13.2%	+17.4%	+24.6%
Aug 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.93	$0.94	+1.4%	+3.9%	-2.9%	+9.0%	+17.6%	+21.9%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.41	$1.43	+1.4%	-3.5%	-5.0%	-8.5%	-7.1%	-7.1%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.54	$1.56	+1.3%	+3.9%	+3.9%	+3.9%	+3.9%	+1.3%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.56	$1.52	-2.6%	+3.8%	-1.3%	+2.6%	+2.6%	+2.6%
Apr 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.58	$1.58	+0.0%	-0.6%	-3.2%	-5.7%	-7.0%	-5.7%
Mar 22	Wedbush	Maintains	Outperform → Outperform	—	$2.24	$2.28	+1.8%	-4.9%	-8.5%	-11.6%	-8.5%	-11.6%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.12	$2.18	+2.8%	+5.7%	+0.5%	-3.3%	-6.6%	-3.3%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.56	$3.52	-1.1%	-3.9%	-4.5%	-9.8%	-9.0%	-11.8%
Jan 31	Jefferies	Maintains	Buy → Buy	—	$3.85	$4.05	+5.2%	+3.9%	+3.6%	+3.1%	+2.6%	+2.3%
Jan 27	Stifel	Maintains	Buy → Buy	—	$3.95	$4.06	+2.8%	-0.3%	-2.5%	+1.3%	+1.0%	+0.5%
Dec 16	EF Hutton	Maintains	Buy → Buy	—	$4.49	$4.66	+3.8%	+2.7%	+4.7%	+6.7%	+14.5%	+17.1%
Nov 10	Raymond James	Maintains	Outperform → Outperform	—	$4.19	$4.37	+4.3%	-2.6%	+6.2%	+11.9%	+13.4%	+7.4%
Nov 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.78	$3.67	-2.9%	+5.6%	+5.8%	+2.1%	+12.4%	+10.8%
May 5	SVB Leerink	Maintains	Outperform → Outperform	—	$1.45	$1.47	+1.4%	+3.4%	+16.6%	+13.1%	+13.1%	+26.9%
Mar 15	Ladenburg Thalmann	Maintains	Buy → Buy	—	$1.44	$1.58	+9.7%	+6.9%	+2.1%	+0.7%	-9.7%	-4.2%
Jan 19	B. Riley Securities	Maintains	Buy → Buy	—	$2.70	$2.92	+8.1%	+4.8%	-0.7%	-10.4%	-14.8%	-23.3%
Dec 22	Raymond James	Maintains	Outperform → Outperform	—	$3.03	$3.11	+2.6%	-1.7%	+0.7%	+0.0%	-3.6%	-3.0%
Dec 20	SVB Leerink	Maintains	Outperform → Outperform	—	$3.05	$3.15	+3.3%	+1.0%	-0.7%	-2.3%	+0.0%	-0.7%
Dec 15	Wedbush	Maintains	Outperform → Outperform	—	$3.18	$3.26	+2.5%	+0.0%	-0.6%	-4.1%	-3.1%	-4.7%

Recent Filings

8-K · 8.01 !! High

Compass Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Compass Therapeutics announced positive Phase 2/3 data for tovecimig combined with paclitaxel in advanced biliary tract cancer, potentially supporting a regulatory filing and expansion of the drug's clinical development.

Apr 27

8-K

Compass Therapeutics, Inc. -- 8-K Filing

Compass Therapeutics' CTX-10726 bispecific antibody advanced to clinical testing with FDA IND clearance, enabling Phase 1 enrollment in Q1 and validating its dual PD-1/VEGF-A targeting approach for potential cancer applications.

Mar 5

Data updated apr 25, 2026 2:02am · Source: massive.com